Investigational drug · Phase 2
Selicrelumab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Pancreatic Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
13
Any phase or sponsor naming "Selicrelumab"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Selicrelumab", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Breast cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Selicrelumab" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03193190 · 341 participants · Start Jul 5, 2017 · Primary completion Feb 27, 2025
Drug: Nab-Paclitaxel; Gemcitabine and 13 more · For: Pancreatic Adenocarcinoma
Sites: Duarte, California; San Francisco, California; New Haven, Connecticut · 23 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02304393 · 140 participants · Start Dec 12, 2014 · Primary completion Nov 7, 2019
Drug: Atezolizumab; Selicrelumab · For: Solid Tumors
Sites: Philadelphia, Pennsylvania; Toronto, Canada; Montreal, Canada · 11 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03555149 · 96 participants · Start Sep 27, 2018 · Primary completion Sep 26, 2022
Drug: Regorafenib; Atezolizumab and 6 more · For: Colorectal Cancer
Sites: Duarte, California; New Haven, Connecticut; Boston, Massachusetts · 15 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02665416 · 94 participants · Start Jan 25, 2016 · Primary completion Oct 30, 2019
Drug: Selicrelumab; Vanucizumab and 1 more · For: Advanced/Metastatic Solid Tumors
Sites: Los Angeles, California; Denver, Colorado; New Haven, Connecticut · 16 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02760797 · 38 participants · Start May 9, 2016 · Primary completion Apr 6, 2018
Drug: Emactuzumab; RO7009789 · For: Neoplasms
Sites: New York, New York; Philadelphia, Pennsylvania; Brussels, Belgium · 6 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00607048 · 34 participants · Start Nov 2007 · Primary completion Jul 2009
Drug: Paclitaxel + Carboplatin + CP-870,893; Paclitaxel + Carboplatin + CP-870,893 · For: Neoplasms
Sites: Los Angeles, California; Santa Monica, California; Philadelphia, Pennsylvania · 4 sites in all
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT01103635 · 25 participants · Start Feb 2010 · Primary completion May 2016
Drug: CD40 agonist monoclonal antibody CP-870,893; tremelimumab · For: Recurrent Melanoma; Stage IV Melanoma
Sites: Philadelphia, Pennsylvania
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
NCT01008527 · 22 participants · Start Oct 2009 · Primary completion Sep 2013
Drug: CP 870,893; Peptides and 1 more · For: Melanoma
Sites: Tampa, Florida
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT01456585 · 10 participants (planned) · Start Apr 2012 · Primary completion Apr 2013
Drug: CP-870,893 · For: Adenocarcinoma Pancreas
Sites: Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Targeting tumor-associated macrophages in pancreatic cancer.
Long Y, Xie L, Xie F, et al. · ILIVER 2026
- Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).
Alshatti N, Lemonnier F, Bachy E, et al. · Immunooncol Technol 2026
- Systemic immune response to a CD40 agonist antibody in nonhuman primates.
Caudell DL, Dugan GO, Babitzki G, et al. · J Leukoc Biol 2024
- Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y, Richmond A, Yan C · Cytokine Growth Factor Rev 2024
- Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Byrne KT, Betts CB, Mick R, et al. · Clin Cancer Res 2021
- Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
Delgado R, Kielbassa K, Ter Burg J, et al. · Cancers (Basel) 2021
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.